Long-term follow-up of UGN-103 for recurrent low-grade non-muscle invasive bladder cancer
Follows adults whose bladder cancer responded to UGN-103 in an earlier study.
Plain-language title generated from the registry record
Registry title: A Rollover Study to Follow the Long-term Durability of Response to UGN-103 in Participants With Recurrent Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (LG-IR-NMIBC) From Study BL013
Key facts
- Where
- Pohja-Tallinna Linnaosa and Tartu Linn, EstoniaSee the 2 sites
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who finished study BL013 with a complete response to UGN-103 that is still ongoing. It follows how long the response lasts.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Non-muscle invasive bladder cancer, recurrent low-grade intermediate-risk, with an ongoing complete response (CR) at the end of study BL013
- Earlier treatment
- Must have completed study BL013 and received UGN-103 in that study
Main reasons for not taking part
- Did not give written informed consent for this rollover study
- Did not complete study BL013 with an ongoing complete response (CR)
Read by machine on 9 November 2026.
Where in Estonia
- Laane-Tallinna Keskhaigla ASPohja-Tallinna Linnaosa, EstoniaTaking people
- Tartu University HospitalTartu Linn, EstoniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Urogen Pharma Ltd.
- Trial code
- EU 2026-526359-75-00
- Record updated
- 15 September 2026
- Original description
Collect long-term durability of response data from participants with an ongoing complete response to UGN-103 at the end of Study BL013Read full original descriptionShow less
A Rollover Study to Follow the Long-term Durability of Response to UGN-103 in Participants From Study BL013
Collect long-term durability of response data from participants with an ongoing complete response to UGN-103 at the end of Study BL013
Inclusion: Participant has provided written informed consent for the rollover study; Participant completed Study BL013 with an ongoing CR.
Exclusion: Participant has not provided written informed consent for the rollover protocol; 2.Participant did not complete Study BL013 with an ongoing CR.